ArticleJACC. Case reports2026
Percutaneous Transcatheter Occlusion of Acquired Gerbode Defect After TAVR.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcquired Gerbode defect is a rare complication of transcatheter aortic valve replacement (TAVR). Percutaneous transcatheter closure is a reasonable yet challenging approach to management. CASE SUMMARY: A 74-year-old man presented with decompensated heart failure after TAVR with a balloon-expanding bioprosthesis (Edwards Sapien). Right heart catheterization revealed left-to-right shunting. Transesophageal echocardiography identified a fistula tract from the left ventricular outflow tract to the right atrium (Gerbode defect). This was closed percutaneously with an Amplatzer atrial septal occluder device (Abbott). Device retrieval and replacement was later required given residual paradevice leak. DISCUSSION: Acquired Gerbode defect is a rare complication of TAVR. There are currently no well-defined predictors, but certain patterns of calcification can be a potential cause. The defect can be successfully closed percutaneously using an atrial septal occluder device. TAKE-HOME MESSAGES: Operators should be aware of the risk of an acquired Gerbode defect after TAVR. Transesophageal echocardiography is required for accurate diagnosis, and the defect can be repaired with a percutaneous transcatheter approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.